COVID-19 Response (VI) - First phase of testing in humans
$3,978,832.00
Grant Value
2020-21
Fiscal Year
Description
Using O-glycan biomarkers, a vaccine against Covid-19 virus will be confirmed as non-toxic and then tested at the clinical level (phase I).
Expected Results
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Grant Details
Recipient
Pharma Glycovax Inc
Location
Montreal, QC H3J 1S6
Agreement Details
Number: 957295
Reference: 172-2020-2021-Q2-957295
Timeline
Start: Aug. 31, 2020
End: July 16, 2021
Program
Industrial Research Assistance Program ? Contributions to Firms
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or …
Sector
Manufacturing (325410)
Your Contribution
Calculate how much you personally contributed to this grant through your taxes.
Calculate My Share